Drug Detail

Information about DCC-3116 + Ripretinib

Generic Name	DCC-3116 + Ripretinib
IND	DCC-3116
Brand Name (US)
Manufacturer	Deciphera
Drug Type	ULK1/2 inhibitor + KIT inhibitor
Delivery	Oral
Approval Status	Phase 1/2
Indications	GIST, CRC
Overall Strategy	Inhibit Adaptive Stress Response (ASR)pathway signaling + inhibit KIT
Strategy	Block ASR autophagy activation + Block KIT
Drug Category	ULK1/2 inhibitor + KIT inhibitor

DCC-3116 is a selective, potent, first-in-class,
investigational inhibitor of ULK1/2 in clinical
development in combination with targeted therapies that
activate the autophagic ASR escape pathway1,2

Links
	AACR 4/18/2023 DCC-3116, a first-in-class selective ULK1/2 inhibitor of autophagy, in combination with the KIT inhibitor ripretinib induces complete regressions in GIST preclinical models

	AACR 4/18/2023 Presentation of New Preclinical Data Highlighting SDiscovery Research Programs at AACR Annual Meeting 2023

	IJ of Molecular Sciences Jan. 4, 2023 Small Molecule Inhibitors for Unc-51-like Autophagy-Activating Kinase Targeting Autophagy in Cancer

	IJ of Molecular Sciences Nov. 17, 2021 Clinical Translation of Combined MAPK and Autophagy Inhibition in RAS Mutant Cancer

Trials of this drug
	A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies

Trial results

Search for this drug/combination in:

ClinicalTrials.gov